<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02950012</url>
  </required_header>
  <id_info>
    <org_study_id>16OBHB</org_study_id>
    <nct_id>NCT02950012</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate OPTI-BIOME™ Bacillus Subtilis MB40 on Abdominal Discomfort, Gas and Bloating in a Healthy Population</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of OPTI-BIOME™ Bacillus Subtilis MB40 on Abdominal Discomfort, Gas and Bloating in a Healthy Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BIO-CAT Microbials, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KGK Science Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BIO-CAT Microbials, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of OPTI-BIOME™ (Bacillus subtilis&#xD;
      MB40), a probiotic supplement, on bloating, gas and abdominal discomfort symptoms in&#xD;
      otherwise healthy adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weekly mean of the daily bloating scores</measure>
    <time_frame>4 weeks</time_frame>
    <description>Discomfort, Gas and Bloating questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weekly mean of the daily gas score (flatulence)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Discomfort, Gas and Bloating questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly mean of the abdominal pain score</measure>
    <time_frame>4 weeks</time_frame>
    <description>Discomfort, Gas and Bloating questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Gastrointestinal Symptom Rating Scale (GSRS) score</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly mean stool consistency scores</measure>
    <time_frame>4 weeks</time_frame>
    <description>Bristol stool scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly mean number of bowel movements</measure>
    <time_frame>4 weeks</time_frame>
    <description>Daily Bowel Habits Diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>4 weeks</time_frame>
    <description>Rand SF-36</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant abnormal vital signs</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant abnormal complete blood panel</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant abnormal electrolytes</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant abnormal kidney function panel</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant abnormal liver function panel</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Bloating</condition>
  <arm_group>
    <arm_group_label>OPTI-BIOME™ Bacillus subtilis MB40</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>OPTI-BIOME™ Bacillus subtilis MB40</intervention_name>
    <arm_group_label>OPTI-BIOME™ Bacillus subtilis MB40</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female 18-75 years (inclusive) of age&#xD;
&#xD;
          2. BMI 18.5-29.9 ±1 kg/m2&#xD;
&#xD;
          3. Abdominal bloating intensity score ≥5 and at least two days of bloating over the 2&#xD;
             weeks prior to screening (assessed at screening by Abdominal Bloating questionnaire)&#xD;
&#xD;
          4. Participants categorized as 'high bloaters' as defined by an average bloating score ≥&#xD;
             5 during the run-in period assessed at baseline by question 3 of the Modified Daily&#xD;
             Abdominal Discomfort, Gas, and Bloating Questionnaire, AND/OR, participants&#xD;
             categorized as 'high frequency bloaters' as defined by greater than 7 days of high&#xD;
             bloating (defined above) during the run-in period.&#xD;
&#xD;
               -  For females, this should not include abdominal discomfort or bloating experienced&#xD;
                  during menstruation, if such symptoms occur due to menstrual cycle females should&#xD;
                  go through another run-in period.&#xD;
&#xD;
          5. If female, participant is not of child bearing potential, which is defined as females&#xD;
             who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are&#xD;
             post-menopausal (natural or surgically with &gt; 1 year since last menstruation) OR&#xD;
&#xD;
             Females of childbearing potential must agree to use a medically approved method of&#xD;
             birth control and have a negative urine pregnancy test result. Acceptable methods of&#xD;
             birth control include:&#xD;
&#xD;
               -  Hormonal contraceptives (stable for 1 month) including oral contraceptives,&#xD;
                  hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing),&#xD;
                  injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant&#xD;
                  System)&#xD;
&#xD;
               -  Double-barrier method&#xD;
&#xD;
               -  Intrauterine devices&#xD;
&#xD;
               -  Non-heterosexual lifestyle or agrees to use contraception if planning on changing&#xD;
                  to heterosexual partner(s)&#xD;
&#xD;
               -  Vasectomy of partner (shown successful as per appropriate follow-up)&#xD;
&#xD;
          6. Healthy as determined by laboratory results, medical history, and physical exam&#xD;
&#xD;
          7. Agrees to abstain from consuming unpasteurized bacteria-fermented foods including&#xD;
             cheese and yogurt for 1 week prior to screening visit and throughout the study&#xD;
&#xD;
          8. Agrees to abstain from using fiber supplements 2 weeks prior to screening and for the&#xD;
             duration of the study&#xD;
&#xD;
          9. Agrees to maintain current dietary habits and activity/training levels for two weeks&#xD;
             prior to baseline and for the course of the study&#xD;
&#xD;
         10. Agrees to avoid probiotics for one week prior to screening and for the course of the&#xD;
             study&#xD;
&#xD;
         11. Willingness to complete all the study requirements and attend all clinic visits.&#xD;
&#xD;
         12. Has given voluntary, written, informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Females who are pregnant, breastfeeding, or planning to become pregnant during the&#xD;
             course of the trial&#xD;
&#xD;
          2. History of chronic inflammation or structural abnormality of the digestive tract&#xD;
             (inflammatory bowel disease, duodenal or gastric ulcer, intestinal obstruction, or&#xD;
             symptomatic cholelithiasis)&#xD;
&#xD;
          3. Nocturnal and/or progressive abdominal pain (abdominal pain that increases in&#xD;
             intensity and is consistent on regular basis)&#xD;
&#xD;
          4. Significant weight loss over the past 3 months (significance to be determined by the&#xD;
             Qualified Investigator)&#xD;
&#xD;
          5. Type 1 and type 2 diabetes&#xD;
&#xD;
          6. History of colorectal cancer, anal abscess, anal fistula, anal fissure, anal stenosis,&#xD;
             gastric retention or obstruction, bowel resection, rectocele, or colostomy&#xD;
&#xD;
          7. Cancer except skin cancers completed excised with no chemotherapy or radiation&#xD;
             following and with a negative follow up.&#xD;
&#xD;
          8. Diagnosis of adenomatous polyposis, irritable bowel syndrome, chronic gastritis or&#xD;
             functional dyspepsia, crohn disease, and celiac disease Renal or hepatic insufficiency&#xD;
&#xD;
          9. Gastrointestinal bleeding or acute infection&#xD;
&#xD;
         10. Immunodeficiency&#xD;
&#xD;
         11. History of organ transplant&#xD;
&#xD;
         12. Use of antibiotics within 4 weeks of randomization Routine (at least 3 times per week)&#xD;
             consumption of probiotic or prebiotic supplements or supplemented foods and are&#xD;
             unwilling to stop at least one week prior to screening and throughout the study&#xD;
&#xD;
         13. Use of immunosuppressant drugs&#xD;
&#xD;
         14. Change in anti-psychotic medication within 3 months of randomization&#xD;
&#xD;
         15. Abdominal surgery within 6 months of randomization&#xD;
&#xD;
         16. Plan to donate blood during the study or within 30 days of completing the study&#xD;
&#xD;
         17. Participation in a clinical research trial within 30 days prior to randomization&#xD;
&#xD;
         18. Allergy or sensitivity to study supplement or placebo ingredients&#xD;
&#xD;
         19. Alcohol abuse (&gt;2 standard alcoholic drinks per day) or drug abuse within the last 6&#xD;
             months&#xD;
&#xD;
         20. Use of Medicinal Marijuana&#xD;
&#xD;
         21. Cognitively impaired and/or unable to give informed consent&#xD;
&#xD;
         22. Unstable medical conditions&#xD;
&#xD;
         23. Clinically significant abnormal laboratory results at screening&#xD;
&#xD;
         24. Any other condition which in the Qualified Investigator's opinion may adversely affect&#xD;
             the volunteer's ability to complete the study or its measures or which may pose&#xD;
             significant risk to the volunteer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tetyana Pelipyagina, MD'</last_name>
    <role>Principal Investigator</role>
    <affiliation>KGK Science Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KGK Clinical Trials Center</name>
      <address>
        <city>Foothill Ranch</city>
        <state>California</state>
        <zip>92610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KGK Clinical Trials Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KGK Synergize Inc.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A5R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 28, 2016</study_first_submitted>
  <study_first_submitted_qc>October 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2016</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>Bloating</keyword>
  <keyword>Abdominal Discomfort</keyword>
  <keyword>Gas</keyword>
  <keyword>Probiotic</keyword>
  <keyword>Bacillus Subtillis</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

